This post was originally published on this site A combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) induces significant survival benefits in people with advanced non-small cell lung cancer (NSCLC), compared to chemotherapy alone, data from a Phase 3 trial show. These findings suggest first-line Opdivo-Yervoy combo as the first immunotherapy to induce better overall…
This post was originally published on this site The chemotherapy agent Jevtana (cabazitaxel) is better than a second course of androgen receptor inhibitors at delaying disease progression and prolonging survival among men with metastatic castration-resistant prostate cancer (mCRPC), a Phase 4 trial shows. All of the participants had seen their disease progress while previously receiving…
This post was originally published on this site ImmunoGen’s investigational therapy mirvetuximab soravtansine effectively delays disease progression in women with ovarian cancer who have high levels of the folate receptor alpha (FRα) protein, compared with chemotherapy, according to exploratory analysis on the data of the FORWARD I Phase 3 trial (NCT02631876). Previous analysis of the…
This post was originally published on this site Aplidin (plitidepsin) in combination with dexamethasone significantly prolonged the survival and time to disease progression or death in heavily treated patients with relapsed or refractory multiple myeloma compared to patients taking dexamethasone alone, a Phase 3 trial shows. The trial’s findings were reported in the study, “Randomized…
This post was originally published on this site Mycophenolate mofetil (MMF) significantly reduced disease symptoms in people with sarcoidosis, and helped to reduce their daily dose of corticosteroids, a small study suggests. The study, “Mycophenolate mofetil as an alternative treatment in sarcoidosis,” was published in the journal of Pulmonary Pharmacology & Therapeutics. Sarcoidosis is characterized by an over-reactive…
This post was originally published on this site Veliparib in combination with chemotherapy significantly prolongs survival without disease progression in women with metastatic HER2-negative breast cancer with BRCA mutations, compared with women on chemotherapy alone, a Phase 3 trial shows. The trial’s findings were presented in a session, titled “Phase 3 study of veliparib with…
This post was originally published on this site The multiple myeloma therapy Velcade (bortezomib) can induce the formation of pro-inflammatory macrophages — a kind of white blood cell — that promote the growth of myeloma tumors, Israeli researchers found. The presence of such cells in the bone marrow could help explain why some myelomas turn…
This post was originally published on this site Using veliparib in combination with chemotherapy as first-line and then maintenance therapy post-surgery significantly extended the time without disease progression in women with newly diagnosed metastatic high-grade serous (HGS) ovarian cancer, according to Phase 3 trial results. The research was presented in the session, “VELIA/GOG-3005: Integration of…
This post was originally published on this site Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, effectively halted cancer progression and reduced tumor size in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), interim data of a Phase 2 trial shows. These results were part of the oral presentation “Interim Evaluation of a Targeted Radiotherapeutic, CLR 131,…
This post was originally published on this site Combination therapy with Lenvima (lenvatinib) and Keytruda (pembrolizumab) continues to show promising antitumor results in patients with advanced endometrial cancer, the most common cancer of the uterus, according to the final results of the KEYNOTE-146/Study 111 trial. The combo was generally well-tolerated, and no new safety signals…
